Johnson Matthey PLC (LON:JMAT – Get Free Report) has received a consensus rating of “Moderate Buy” from the five analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is GBX 2,320.
Several equities research analysts recently commented on the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 2,400 price objective on shares of Johnson Matthey in a report on Monday, July 6th. Jefferies Financial Group restated a “buy” rating and set a GBX 2,330 target price on shares of Johnson Matthey in a research note on Tuesday, August 4th.
Get Our Latest Research Report on Johnson Matthey
Johnson Matthey Stock Up 0.3%
JMAT stock opened at GBX 2,470 on Tuesday. Johnson Matthey has a 1-year low of GBX 2,192 and a 1-year high of GBX 3,245.33. The business has a fifty day moving average price of GBX 2,348.45 and a 200-day moving average price of GBX 2,150.05. The company has a debt-to-equity ratio of 69.69, a current ratio of 1.56 and a quick ratio of 0.76. The stock has a market capitalization of £3.11 billion, a P/E ratio of -32.39, a P/E/G ratio of 49,242.50 and a beta of 0.88.
Insiders Place Their Bets
In related news, insider Richard Pike bought 17,635 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was acquired at an average cost of GBX 2,248 per share, for a total transaction of £396,434.80. Also, insider Liam Condon bought 10,951 shares of the firm’s stock in a transaction on Friday, September 11th. The shares were bought at an average price of GBX 2,306 per share, with a total value of £252,530.06. In the last quarter, insiders purchased 28,608 shares of company stock valued at $64,947,512. Company insiders own 0.77% of the company’s stock.
Johnson Matthey Company Profile
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers’ products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources. Today more than 13,000 Johnson Matthey professionals collaborate with their network of customers and partners to make a real difference to the world around us.
See Also
- Five stocks we like better than Johnson Matthey
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Johnson Matthey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Matthey and related companies with MarketBeat.com's FREE daily email newsletter.
